PD1-CD19-CART

PD1-CD19-CART is a **genetically engineered chimeric antigen receptor T cell therapy (CAR-T)** targeting the CD19 antigen on B cells for the treatment of hematologic malignancies, primarily B-cell lymphomas and leukemias. This therapy incorporates either a PD-1 domain or a PD-1/CD28 chimeric switch receptor into the CAR structure. These modifications aim to overcome T-cell exhaustion and immune suppression mediated by the tumor PD-1/PD-L1 axis. The **mechanism of action** involves redirecting patient T cells to target CD19-positive cancer cells while also mitigating inhibitory signals from PD-1, either by blocking the negative signaling (via PD-1 knockout, switch receptor, or antibody blockade) or by switching it to an activating CD28 signal, thus enhancing T cell proliferation, cytokine release, and antitumor cytotoxicity[5][7].

Other names

PD-1/CD19 CAR-TCD19-PD-1/CD28-CAR-TCD19-PD-1/CD28-CART